New genetic discoveries and treatment for hepatitis C

JAMA

Volumn 307, Issue 18, 2012, Pages 1921-1922

  Pacanowski, Michael ^a   Amur, Shashi ^a   Zineh, Issam ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BOCEPREVIR; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; RIBAVIRIN; TELAPREVIR;

ANTIVIRAL THERAPY; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; GENE; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS C; HUMAN; INTERLEUKIN 28B GENE; MEDICAL DECISION MAKING; PHARMACOGENETICS; PRIORITY JOURNAL; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; VIRUS GENE;

EID: 84860730800     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.3516     Document Type: Short Survey

References (6)

1. Clark PJ, Thompson AJ, McHutchison JG. IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. Am J Gastroenterol. 2011;106(1):38-45.
2. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139(1): 120-129.
3. Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433-1444.
4. Guidance for industry: chronic hepatitis c virus infection: developing direct-acting antiviral agents for treatment (draft). US Food and Drug Administration. http://www .fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances /UCM225333.pdf. Accessed April 11, 2012.
5. Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature. 2010;464(7287):405-408.
6. Armstrong K. Can genomics bend the cost curve? JAMA. 2012;307(10):1031- 1032.